BioSpace News Archive

Umoja Biopharma, Inc. today announced new data from an ongoing non-human primate (NHP) study demonstrating effective, durable, and well tolerated in vivo chimeric antigen receptor (CAR) T cell generation using the Company’s VivoVec™ platform technology at the 8th CAR-TCR Summit taking place in Boston, MA, August 29 - September 1, 2023.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study.

X4 Pharmaceuticals announced that, effective on August 31, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 58,850 restricted stock units to six newly-hired employees.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 6,800 shares of G1’s common stock and 3,300 restricted stock units to two hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

ORIC Pharmaceuticals, Inc. announced that on September 1, 2023, ORIC granted a total of 19,380 non-qualified stock options and 3,220 restricted stock units to three new non-executive employees who began their employment with ORIC in August 2023.

Zentalis® Pharmaceuticals, Inc. announced that on September 1, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 32,975 shares of the Company’s common stock to four newly hired employees.

Ligand Pharmaceuticals Incorporated announced that on September 1, 2023, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 50,000 shares of its common stock to one non-executive employee in connection with the employee’s commencement of employment under the Ligand Pharmaceuticals Incorporated 2022 Employee Inducement Plan.

Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will present at the 2023 Wells Fargo Healthcare Conference on September 6, 2023 at 1:30 p.m. EST.